Get Premium to unlock powerful stock data
NYSE:NVO (Denmark)  
Novo Nordisk A/S logo

Novo Nordisk A/S

$ 111.24 -0.4 (-0.36%) 10:08 PM EST
P/E:
37.00
P/B:
27.19
Market Cap:
$ 251.89B
Enterprise V:
$ 251.06B
Volume:
2.52M
Avg Vol (2M):
1.47M
Also Trade In:
Volume:
2.52M
Market Cap $:
251.89B
PE Ratio:
37.00
Avg Vol (2-Month):
1.47M
Enterprise Value $:
251.06B
PB Ratio:
27.19
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Description
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Financials (Next Earnings Date:2022-07-07 Est.)

NVO's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NYSE:NVO

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 23,038.015
EPS (TTM) ($) 3.33
Beta 0.36
Volatility % 25.15
14-Day RSI 53.59
14-Day ATR ($) 2.720123
20-Day SMA ($) 110.0475
12-1 Month Momentum % 32.54
52-Week Range ($) 84.55 - 122.16
Shares Outstanding (Mil) 2,264.34

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 8
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Novo Nordisk A/S Filings

Document Form Filing Date
No Filing Data

Headlines

See More